Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „differences“
Suchtreffer
Begriffe & Kennungen
Capecitabine Medac · 4.5 · Oxaliplatin No clinically significant differences in exposure to capecitabine or its metabolites, free platinu
Eintrag öffnenCapecitabine Teva · 4.5 · Oxaliplatin No clinically significant differences in exposure to capecitabine or its metabolites, free platinu
Eintrag öffnenDifferenzierungsschwelle
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Oxaliplatin: no clinically significant differences in exposure to capecitabine or its metabolites, free platin
Eintrag öffnenElocta · 4.8 · Paediatric population No age-specific differences in adverse reactions were observed between paediatric and ad
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnbrel · 4.8 · There were no differences in rates of infection among patients treated with Enbrel and those treated with plac
Eintrag öffnenEnhertu · 4.8 · Ethnic differences
Eintrag öffnenEnhertu · 4.8 · In clinical studies, no relevant differences in exposure or efficacy were observed between patients of differe
Eintrag öffnenEntyvio · 4.8 · No clinically relevant differences in the overall safety profile and adverse reactions were observed in patien
Eintrag öffnenEpysqli · 4.8 · Elderly No overall differences in safety were reported between elderly (≥ 65 years) and younger refractory gMG
Eintrag öffnenErelzi · 4.8 · There were no differences in rates of infection among patients treated with etanercept and those treated with
Eintrag öffnenErvebo · 4.8 · 8 recurrent arthritis) with a maximum of 330 days. The reasons for differences in arthritis reporting across s
Eintrag öffnenFilgrastim Hexal · 4.8 · No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared
Eintrag öffnenGeschlechtsmerkmale
Eintrag öffnenHetronifly · 4.8 · No overall differences in safety were reported between elderly (≥ 65 years) and younger patients. Data for pat
Eintrag öffnen